Gilead Lobbying Rose As Interest In COVID-19 Treatment Climbed

By Sydney Lupkin

Published May 2, 2020 at 7:00 AM MDT

Facebook
Twitter
LinkedIn
Email

On Friday, the Food and Drug Administration authorized emergency use of remdesivir for patients with severe cases of COVID-19. Drugmaker Gilead Sciences' lobbying hit a new high in the first quarter.

NPR Coronavirus Updates

Facebook
Twitter
LinkedIn
Email

Sydney Lupkin

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

See stories by Sydney Lupkin